AQR Capital Management
HRTX icon

AQR Capital Management’s Heron Therapeutics HRTX Stock Holding History

AQR Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$513K Buy
641,587
+265,287
+70% +$307K ﹤0.01% 3107
2025
Q4 		$489K Sell
376,300
-1,560,389
-81% -$1.93M ﹤0.01% 2925
2025
Q3 		$2.44M Buy
1,936,689
+1,874,940
+3,036% +$2.97M ﹤0.01% 1864
2025
Q2 		$128K Buy
61,749
+34,440
+126% +$70.3K ﹤0.01% 3138
2025
Q1 		$60.1K Sell
27,309
-187,648
-87% -$364K ﹤0.01% 3072
2024
Q4 		$329K Sell
214,957
-685,150
-76% -$1.11M ﹤0.01% 2458
2024
Q3 		$1.79M Buy
900,107
+292,972
+48% +$700K ﹤0.01% 1559
2024
Q2 		$2.12M Buy
607,135
+568,238
+1,461% +$1.75M ﹤0.01% 1427
2024
Q1 		$108K Buy
38,897
+2,042
+6% +$5.13K ﹤0.01% 2331
2023
Q4 		$62.7K Sell
36,855
-85,912
-70% -$94.6K ﹤0.01% 2301
2023
Q3 		$126K Sell
122,767
-25,184
-17% -$35.8K ﹤0.01% 2199
2023
Q2 		$172K Buy
147,951
+6,874
+5% +$12.3K ﹤0.01% 2100
2023
Q1 		$213K Buy
141,077
+89,717
+175% +$225K ﹤0.01% 2036
2022
Q4 		$128K Sell
51,360
-1,908
-4% -$6.15K ﹤0.01% 2122
2022
Q3 		$225K Buy
+53,268
New +$208K ﹤0.01% 2018
2019
Q2 		– Sell
-13,202
Closed -$323K – 2124
2019
Q1 		$323K Buy
+13,202
New +$346K ﹤0.01% 1948
2014
Q3 		– Sell
-75,000
Closed -$924K – 2548
2014
Q2 		$924K Buy
+75,000
New +$896K ﹤0.01% 1690

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

AQR Capital Management's HRTX Position: Q1 2026 in Review

AQR Capital Management increased its Heron Therapeutics (HRTX) stake by 70% in Q1 2026, buying an estimated $307K and bringing the position to 641,587 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #3107.

AQR Capital Management first reported a position in HRTX in Q2 2014 and has held it in 17 quarters since. The position peaked at $2.44M in Q3 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • AQR Capital Management held 641,587 shares of Heron Therapeutics worth $513K as of Q1 2026.
  • AQR Capital Management bought 265,287 Heron Therapeutics shares in Q1 2026, an estimated $307K.
  • Heron Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3107 holding.
  • AQR Capital Management first reported a position in Heron Therapeutics in Q2 2014 and has held it in 17 quarters since.
  • AQR Capital Management's Heron Therapeutics position peaked at $2.44M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.